Your browser is no longer supported. Please, upgrade your browser.
Decibel Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own9.50% Shs Outstand24.20M Perf Week0.33%
Market Cap437.29M Forward P/E- EPS next Y- Insider Trans183.05% Shs Float- Perf Month-
Income-43.70M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y-18.20% Inst Trans- Short Ratio0.00 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.21 P/C84.09 EPS next 5Y- ROE- 52W Range17.67 - 24.39 Perf YTD0.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.01% Beta-
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low3.51% ATR1.48
Employees37 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)- Volatility4.84% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.16 Prev Close18.07
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume493.85K Price18.29
Recom- SMA20-1.33% SMA50-1.33% SMA200-1.33% Volume7,267 Change1.22%
Feb-24-21 07:00AM  
Feb-19-21 07:00AM  
Feb-12-21 05:05PM  
Feb-11-21 09:51PM  
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLCDirectorFeb 17Buy18.00150,0002,700,0001,183,663Feb 19 04:50 PM
ORBIMED ADVISORS LLCDirectorFeb 17Buy18.001,666,66629,999,9883,843,206Feb 19 07:09 PM
Foy MatthewDirectorFeb 17Buy18.00150,0002,700,0001,183,663Feb 19 06:59 PM
Casdin Partners Master Fund, L10% OwnerFeb 17Buy18.00575,00010,350,0001,121,421Feb 19 06:56 PM
Thompson Peter A.DirectorFeb 17Buy18.001,666,66629,999,9883,843,206Feb 19 06:50 PM